| Superficial Therapy | Radiant | Xstrahl 100 | Xstrahl 150 | Xstrahl 200 | Xstrahl 300 |
|---|---|---|---|---|---|
| Basal Cell Carcinoma (BCC) |  | | | | |
| Squamous Cell Carcinoma (SCC) |  | | | | |
| Bowen’s Disease | | | | | |
| Merkel Cell Carcinoma | | | | ||
| Lentigo Maligna | | | |||
| Mycosis Fungoides | | | | |
| Benign Conditions | Radiant | Xstrahl 100 | Xstrahl 150 | Xstrahl 200 | Xstrahl 300 |
|---|---|---|---|---|---|
| Keloid Scars | | | | | |
| Morbus Ledderhose | | | | ||
| Dupuytren’s Contracture | | | |
| Palliative Care | Radiant | Xstrahl 100 | Xstrahl 150 | Xstrahl 200 | Xstrahl 300 |
|---|---|---|---|---|---|
| Soft Tissue Metastases | | | |||
| Bony Metastases | | |
Contact Us
Find out more about why Xstrahl will work tirelessly for you
Explore Related Posts
Reaching Out to Improve Access to Radiation Therapy
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Xstrahl to feature Radiant™ Aura at ASTRO 2023
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
Antagonistic Effects of Ionising Radiation in Cell Competition
David Fernandez-Antoran PhD, Group Leader, The Gurdon Institute, University of Cambridge, Cambridge, UK ARAID Researcher, Head of Cell Competition and Radiation Biology Laboratory, IIS-Aragon, Zaragoza, Spain Ionising radiation is one of the most common environmental...